France starts third clinical trial phase of its own Covid vaccine

According to Olivier Bogillot, the head of the company, the vaccine may be available until December 2021.

Olivier Bogillon assured that unlike Pfizer-BioNTech, AstraZeneca, Moderna, and Janssen, the French vaccine does not use mRNA technology. It will be based on a recombinant protein, as in modern flu vaccinations. He noted that in combination with a special substance, the immune response will be active and will last longer.

This is a technology we use to vaccinate against influenza, a proven technology that we have been using for several years," he clarified.

Among the benefits of the French coronavirus vaccine, Bogillot named low-cost production and milder storage requirements. In addition, the low cost of the drug will help the less developed countries.

Meanwhile, India's Bharat Biotech said its Covaxin vaccine is 93.4% effective against severe Covid-19. These results were established during the third phase of drug testing.

As reported before, Janssen (Johnson & Johnson) Covid-19 vaccine for emergency medical use has been registered in Ukraine.

In addition, this month, Ukraine will get two million doses of Moderna vaccine; they will arrive from the U.S., as part of the COVAX global mechanism.

 

Source: France starts third clinical trial phase of its own Covid vaccine - France starts third clinical trial phase of its own Covid vaccine - 112.international

 

Share this page Share on FacebookShare on TwitterShare on Linkedin
Close

Discover the 'Made in France à Bahrain' Guide

'Made in France à Bahrain' - Edition 2021
is YOUR guide to the economic presence in Bahrain. Click here to view the online guide